We are live on ! Find out more
BCAX

Bicara Therapeutics
BCAX

106 hedge funds and large institutions have $475M invested in Bicara Therapeutics in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 16

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

14% more funds holding

Funds holding: 93 → 106 (+13)

4.5% more ownership

Funds ownership: 89.32% → 93.82% (+4.5%)

25% less capital invested

Capital invested by funds: $634M → $475M (-$159M)

54% less call options, than puts

Call options by funds: $11K | Put options by funds: $24K

Holders
106
Holders Change
+13
Holders Change %
+13.98%
% of All Funds
1.4%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
33
Increased
43
Reduced
16
Closed
19
Calls
$11K
Puts
$24K
Net Calls
-$13K
Net Calls Change
-$12K

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$26.6M
2
SL
Siren LLC
Connecticut
+$23.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.9M
4
BlackRock
BlackRock
New York
+$9.17M
5
Millennium Management
Millennium Management
New York
+$8.53M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$28.2M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.2M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$18M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$15.4M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$3.12M – – –
DCM
27
DAFNA Capital Management
California
$2.94M +$1.25M +105,000 +50%
NTIC
28
Napean Trading & Investment Company
Singapore
$2.56M – – –
RAM
29
Readystate Asset Management
Illinois
$2.51M +$3.22M +270,200 New
SSA
30
Schonfeld Strategic Advisors
New York
$2.44M -$1.23M -103,213 -28%
Northern Trust
31
Northern Trust
Illinois
$2.15M +$922K +77,401 +50%
TD Asset Management
32
TD Asset Management
Ontario, Canada
$2.09M +$1.12M +93,600 +71%
Citadel Advisors
33
Citadel Advisors
Florida
$2.06M +$2.64M +221,516 New
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$2.01M +$2.58M +216,836 New
Morgan Stanley
35
Morgan Stanley
New York
$1.9M -$11.3M -947,671 -82%
SAM
36
Sectoral Asset Management
Quebec, Canada
$1.87M +$2.4M +201,395 New
Charles Schwab
37
Charles Schwab
California
$1.79M +$477K +40,049 +26%
SCM
38
Superstring Capital Management
New York
$1.76M +$2.26M +189,699 New
Verition Fund Management
39
Verition Fund Management
Connecticut
$1.59M +$2.04M +170,962 New
Goldman Sachs
40
Goldman Sachs
New York
$1.41M +$312K +26,162 +21%
HP
41
HealthInvest Partners
Sweden
$1.37M +$328K +27,547 +23%
Two Sigma Investments
42
Two Sigma Investments
New York
$1.25M +$1.45M +121,687 +953%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.17M +$682K +57,222 +83%
Deutsche Bank
44
Deutsche Bank
Germany
$1.15M +$151K +12,702 +11%
JG
45
Jain Global
New York
$1.1M +$1.41M +117,910 New
CSS
46
Cubist Systematic Strategies
Connecticut
$952K +$1.22M +102,525 New
Skandinaviska Enskilda Banken (SEB)
47
Skandinaviska Enskilda Banken (SEB)
Sweden
$922K +$729K +61,201 +161%
CCM
48
Catalio Capital Management
New York
$909K +$1.17M +97,800 New
UBS Group
49
UBS Group
Switzerland
$814K +$259K +21,752 +33%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$747K +$456K +38,236 +91%
1
2
3 4 5

BCAX Hedge Fund Activity: Q2 2025 in Review

106 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q2 2025, worth a combined $475M — down 25% from $634M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BCAX positions and 19 closed out — a net gain of 14 holders — while 43 added to existing stakes and 16 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $26.6M. The largest seller was Braidwell, exiting entirely with an estimated $28.2M sold.

  • 106 institutional investors held Bicara Therapeutics (BCAX) as of Q2 2025, up from 93 in Q1 2025.
  • Funds reported $475M of Bicara Therapeutics stock for Q2 2025, down 25% quarter-over-quarter.
  • 33 funds opened new Bicara Therapeutics positions in Q2 2025 and 19 closed out, a net change of +14 holders.
  • The largest Bicara Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $26.6M added.
  • The largest Bicara Therapeutics seller in Q2 2025 was Braidwell, an estimated $28.2M sold.

Based on aggregated 13F filings for Q2 2025.